Canada's Cangene Corp. said Monday that it won approval
from Health Canada for its anti-chicken pox treatment for pregnant women
previously not infected with the virus. The drug was investigated
for its ability to prevent chicken pox in pregnant women who had been
accidentally exposed to the virus and who were not previously immune.
a great development for Cangene - now we have successfully taken two
hyperimmune products through the development and approval process and on to
the market," said Dr. John Langstaff, Cangene's president and CEO. VariZIG's
approval in Canada allows Cangene to market the product in a number of other
countries. Cangene intends to pursue applications in other jurisdictions.
VariZIG(tm) is purified from specially
collected human plasma and manufactured using an industry-leading combination
of solvent-detergent and nanofiltration for virus inactivation. These antibody
products are generally referred to as hyperimmunes. Cangene believes
hyperimmune products to be key weapons against infectious disease and is
developing several others with infectious disease targets. Two of these are
anti-Hepatitis B and anti-Hepatitis C, which are in advanced clinical
Cangene's website, www.cangene.com, includes product and investor information,
including past news releases.